Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-067379 Act: 34 Size: 41 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 5.02 Accession Number: 0001104659-20-066371 Act: 34 Size: 16 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-20-006259 Act: 34 Size: 6 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-20-059553 Act: 34 Size: 148 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-056348 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-056349 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-056350 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-056351 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-056352 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-056355 Size: 4 KB 网页链接